Lumbrokinase

Phase 3

XXinqiao Hospital of Chongqing

Lumbrokinase is one of 5 therapeutic programs targeting Ischemic Stroke, Acute. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ischemic Stroke, AcuteNot yet recruiting

Ischemic Stroke, AcutePhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Ischemic Stroke, Acute

#DrugCompanyPhaseTrials

Minocin

TTriax

Approved

1 2

Aggrastat

MMedicure

Approved

1 3

Alteplase or Tenecteplase

CChinese University of Hong Kong

Phase 3

1 4

Non-Immunogenic Staphylokinase

SSupergene, LLC

Phase 3

1 5

Lumbrokinase

XXinqiao Hospital of Chongqing

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedNot yet recruiting

Ischemic Stroke, Acute

NCT07763405

Clinical

Trials by Indication[1]

Ischemic Stroke, Acute1 trial

Efficacy and Safety of Lumbrokinase Versus Placebo in Moderate-to-Severe Ischemic Stroke: A Multicenter, Randomized, Double-Blind Clinical Trial

Not yet recruiting·XXinqiao Hospital of Chongqing·Approved·NCT07763405·1,196 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lumbrokinase. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lumbrokinase. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xinqiao Hospital of Chongqing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: XXinqiao Hospital of Chongqing

Lumbrokinase

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Ischemic Stroke, Acute1 trial

References

Drug Info

Quick Facts

Related News